{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:59:26Z","timestamp":1792508366147,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jtct.2023.04.022","type":"journal-article","created":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T01:14:10Z","timestamp":1683422050000},"page":"505.e1-505.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation"],"prefix":"10.1016","volume":"29","author":[{"given":"Yarden Irit","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5215-7278","authenticated-orcid":false,"given":"Eyal","family":"Lebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5483-5180","authenticated-orcid":false,"given":"Eran","family":"Zimran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9620-781X","authenticated-orcid":false,"given":"Adir","family":"Shaulov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Stepensky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-6326","authenticated-orcid":false,"given":"Sigal","family":"Grisariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batia","family":"Avni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.04.022_bib0001","article-title":"High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults","volume":"1","author":"Schaaf","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtct.2023.04.022_bib0002","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/asheducation-2015.1.74","article-title":"What is the role of autologous transplant for lymphoma in the current era?","volume":"2015","author":"Stiff","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2023.04.022_bib0003","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.hoc.2021.09.004","article-title":"Primary central nervous system lymphomas","volume":"36","author":"Chukwueke","year":"2022","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jtct.2023.04.022_bib0004","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11899-017-0382-1","article-title":"A review of autologous stem cell transplantation in lymphoma","volume":"12","author":"Zahid","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.04.022_bib0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hon.2589","article-title":"Treating Hodgkin lymphoma in the new millennium: relapsed and refractory disease","volume":"37","author":"LaCasce","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jtct.2023.04.022_bib0006","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.hemonc.2021.03.005","article-title":"Comparison of mitoxantrone-melphalan and BEAM conditioning regimens in patients with lymphoma","volume":"15","author":"Gunes","year":"2022","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.jtct.2023.04.022_bib0007","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","article-title":"Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.022_bib0008","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ccm.2017.07.002","article-title":"Noninfectious acute lung injury syndromes early after hematopoietic stem cell transplantation","volume":"38","author":"Ahya","year":"2017","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.jtct.2023.04.022_bib0009","first-page":"104","article-title":"Incidence and risk factors for the development of idiopathic pneumonitis syndrome (IPS) after autologous hematopoietic cell transplantation (AutoHCT) for patients with lymphoma","volume":"20","author":"Chen","year":"2014","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.04.022_bib0010","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.clml.2018.02.008","article-title":"Thiotepa, etoposide, cyclophosphamide, cytarabine, and melphalan (TECAM) conditioning regimen for autologous stem cell transplantation in lymphoma","volume":"18","author":"Grisariu","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2023.04.022_bib0011","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/sj.bmt.1705838","article-title":"The effect of high-dose thiotepa, alone or in combination with other chemotherapeutic agents, on a murine B-cell leukemia model simulating autologous stem cell transplantation","volume":"40","author":"Abdul-Hai","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.022_bib0012","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1200\/JCO.2007.15.5507","article-title":"Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma","volume":"26","author":"Goodman","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.04.022_bib0013","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/bmt.2017.205","article-title":"Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin's and non-Hodgkin's B-cell Lymphoma","volume":"53","author":"Joffe","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.022_bib0014","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.04.022_bib0015","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.04.022_bib0016","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.04.022_bib0017","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/bmt.2015.273","article-title":"Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT","volume":"51","author":"Sellner","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.022_bib0018","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1080\/10428194.2020.1765238","article-title":"BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant","volume":"61","author":"Marchesi","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2023.04.022_bib0019","first-page":"104","article-title":"Long-term outcomes of autologous hematopoetic cell transplant (AHCT) following thiotepa-based high-dose therapy (HDT) in patients with non-Hodgkin lymphoma (NHL)","volume":"20","author":"Shah","year":"2014","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.04.022_bib0020","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1700913","article-title":"BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors","volume":"20","author":"Caballero","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.04.022_bib0021","doi-asserted-by":"crossref","first-page":"8","DOI":"10.21037\/aol.2017.11.01","article-title":"Disparities in lymphoma on the basis of race, gender, HIV status, and sexual orientation","volume":"1","author":"Becnel","year":"2017","journal-title":"Ann Lymphoma"},{"key":"10.1016\/j.jtct.2023.04.022_bib0022","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood.2021013289","article-title":"Autologous transplantation vs chimeric antigen T cell therapy for relapsed DLBCL in partial remission","volume":"139","author":"Shadman","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.04.022_bib0023","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.04.022_bib0024","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2023.04.022_bib0025","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/jamaoncol.2021.1074","article-title":"Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant","volume":"7","author":"Scordo","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2023.04.022_bib0026","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","article-title":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","volume":"36","author":"Ferreri","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.04.022_bib0027","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.9807","article-title":"Comparison of allogeneic stem cell transplant and autologous stem cell transplant in refractory or relapsed peripheral T-cell lymphoma: a systematic review and meta-analysis","volume":"4","author":"Du","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723012605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723012605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:10:47Z","timestamp":1763003447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723012605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2666636723012605"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.04.022","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}